PATENT P-3023-US1

OCT U 1 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

APPLICANT(S):

Martin B. Wax

SERIAL NO.:

09/591,561

EXAMINER: Eileen B. O'Hara

FILED:

June 13, 2000

ART UNIT: 1646

FOR:

METHODS FOR TREATING GLAUCOMA

AMENDMENT IN RESPONSE TO JUNE 1, 2001 RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Dear Sir:

22.

This Amendment is filed in response to the Office Action dated June 1, 2001 issued by the United States Patent and Trademark Office in connection with the above-identified Application. A response to the June 1, 2001 Office Action is due July 1, 2001. Applicants are concurrently filing herewith a Petition for a Four-Month Extension of Time, in connection with the subject Application. Therefore, a response is now due October 1, 2001. Accordingly, this Amendment is being timely filed.

Please amend the subject Application as follows:

IN THE CLAIMS:

Please amend claims 1, 16 and 17 as follows:

- 1. A method for treating a subject with glaucoma comprising the steps of administrating a compound or composition containing an agent or molecule, which antagonizes, inhibits, inactivates, reduces, suppresses, and/or limits the release, synthesis, or production from cells of $TNF-\alpha$ thereby treating the subject with glaucoma.
- 16. The method of claim 1, wherein said compound or composition further comprises a diluent and suitable carrier.
- 17. The method of claim 1, wherein the compound or composition is administered ocularly, parenterally, transmucosally, transdermally, intramuscularly, intravenously, intradermally,